iBio, Inc.
IBIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IBIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IBIO
iBio, Inc. is a preclinical-stage biotechnology company using an AI-driven platform to develop next-generation antibody medicines for obesity and cardiometabolic diseases.
Key risk: Preclinical stage with no revenue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$67.6M
Cash Runway
—
Lead Asset
ibio-600 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for iBio, Inc..
iBio, Inc. is a preclinical-stage biotechnology company using an AI-driven platform to develop next-generation antibody medicines for obesity and cardiometabolic diseases.
- iBio is a preclinical-stage company leveraging AI and machine learning to discover hard-to-drug precision antibodies for cardiometabolic and obesity indications [sec · filed 2025-08-18].
- The company has not yet generated material revenue from its platform and expects to incur net losses and negative cash flows for the foreseeable future [sec_mda · as of 2026-02-10].
- As of June 30, 2026, iBio reported cash and equivalents of $56.6 million and shareholders' equity of $14.9 million [sec].
- iBio has raised capital through public offerings and warrant exercises, including approximately $50 million from an August 2025 underwritten public offering and $26 million from a January 2026 private placement [sec_mda · as of 2026-05-12].
- The company aims to become a clinical-stage company by advancing its pipeline and evaluating partnerships for its obesity assets [sec_mda · as of 2026-02-10].
What works
- iBio's AI-driven discovery platform is designed to unlock targets that have been difficult for other scientists to drug, potentially offering a competitive edge in the obesity and cardiometabolic space [sec_mda · as of 2026-05-12].
- The company has raised significant capital through multiple financing rounds, including a $50 million public offering and a $26 million private placement, providing cash runway to advance preclinical programs [sec_mda · as of 2026-05-12].
- iBio's strategic focus on capital-efficient drug discovery and potential partnerships could accelerate development timelines and reduce financial risk [sec_mda · as of 2026-02-10].
What to weigh
- iBio is a preclinical-stage company with no approved products or revenue from its platform, and it expects to incur net losses and negative cash flows for many years [sec_mda · as of 2026-02-10].
- The company's future revenue depends on successful development, regulatory approval, and commercialization of its product candidates, which are subject to significant clinical and regulatory risks [sec_mda · as of 2026-05-12].
- iBio has a history of operating deficits, with a net loss of $14.7 million and negative cash flows from operations of $10.9 million for the six months ended December 31, 2025 [sec_mda · as of 2026-02-10].
From the filings
Quoted directly from source documents.
iBio is a preclinical-stage company using AI for antibody discovery.
“We are a preclinical stage biotechnology company leveraging the power of Artificial Intelligence ("AI") for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space.”
SEC filings · August 18, 2025
iBio has not generated material revenue from its platform.
“To date this platform has not generated any material revenue, though we may realize revenue from it in the future.”
SEC MD&A · February 10, 2026
iBio raised $50 million in an August 2025 public offering.
“In August 2025, we closed on an underwritten public offering raising gross proceeds of approximately $50 million”
SEC MD&A · May 12, 2026
iBio had a net loss of $14.7 million for six months ended December 31, 2025.
“For the six months ended December 31, 2025, we incurred a net loss of approximately $14.7 million”
SEC MD&A · February 10, 2026
Catalyst timeline
- 2026-05-24 · Phase 1 Start — A Phase 1, first-in-human clinical trial initiation for a lead candidate is a key milestone to watch.
Risks & what to watch (4)›
Key risks
- Preclinical stage with no revenue — iBio has no approved products or revenue from its platform; future revenue depends on successful development and commercialization [sec_mda · as of 2026-02-10].
- Significant operating losses — The company incurred a net loss of $14.7 million for the six months ended December 31, 2025, with negative cash flows [sec_mda · as of 2026-02-10].
- Dependence on financing — iBio's liquidity has historically relied on equity sales and warrant exercises; future capital needs may require additional financing [sec_mda · as of 2026-05-12].
- Clinical and regulatory uncertainty — Product candidates are subject to clinical trial outcomes, FDA review timelines, and market acceptance risks [sec_mda · as of 2026-05-12].
What to watch
- Initiation of Phase 1 clinical trial for lead candidate, as indicated by a Phase 1 start catalyst on 2026-05-24 [catalyst].
- Progress of preclinical pipeline toward becoming a clinical-stage company [sec_mda · as of 2026-02-10].
- Potential partnership or out-licensing deals for obesity assets to accelerate development [sec_mda · as of 2026-02-10].
- Future capital raises or warrant exercises to extend cash runway [sec_mda · as of 2026-05-12].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run iBio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available iBio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.16
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$27.0M
| Holder | Shares | Value |
|---|---|---|
| affinity asset advisors, llc | 3,107,200 | $5.9M |
| vanguard capital management llc | 2,176,598 | $4.1M |
| millennium management llc | 1,549,850 | $2.9M |
| balyasny asset management l.p. | 1,010,955 | $1.9M |
| citadel advisors llc | 956,429 | $1.8M |
| walleye capital llc | 777,108 | $1.5M |
| marshall wace, llp | 620,602 | $1.2M |
| adar1 capital management, llc | 469,878 | $893K |
| susquehanna international group, llp | 412,725 | $784K |
| two sigma investments, lp | 408,858 | $777K |
Showing top 10 of 47 institutional holders of iBio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.5%
- Days to cover
- 4.3
- Shares short
- 3,416,605
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IBIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for iBio, Inc.?
iBio, Inc. is a preclinical-stage biotechnology company using an AI-driven platform to develop next-generation antibody medicines for obesity and cardiometabolic diseases.
What is iBio, Inc.'s lead drug candidate?
iBio, Inc.'s most advanced tracked candidate is ibio-600 (Phase 1) for Overweight , Obesity.
Who is the CEO of iBio, Inc.?
Dr. Martin B. Brenner D.V.M., Ph.D. is the chief executive officer of iBio, Inc. (IBIO).
Where is iBio, Inc. headquartered?
iBio, Inc. (IBIO) is headquartered in San Diego, CA, United States.
What therapeutic areas does iBio, Inc. focus on?
iBio, Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.